Therapeutic drug monitoring of oral targeted antineoplastic drugs

2020198 citationsReviewhybrid Open Access

Authors

Anna Mueller‐Schoell · University of Applied Sciences Potsdam

Stefanie L. Groenland · The Netherlands Cancer Institute

Oliver Scherf‐Clavel · University of Würzburg

Madelé van Dyk · Flinders University

Wilhelm Huisinga · University of Potsdam

Robin Michelet · Freie Universität Berlin

Ulrich Jaehde

Abstract

Sub-therapeutic concentrations and severe adverse events are current challenges in OAD treatment, which can both be addressed by the application of TDM-guided dosing, ensuring concentrations within the therapeutic window.

Topics & Keywords

Neuroendocrine Tumor Research Advances Chronic Myeloid Leukemia Treatments Lung Cancer Treatments and Mutations

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: European Journal of Clinical Pharmacology

Volume 77, Issue 4, pp. 441-464

DOI: 10.1007/s00228-020-03014-8

Field-Weighted Citation Impact: 17.47